848440-23-3

Basic information

• Product Name: Carbamic acid, (3-bromo-2-fluorophenyl)-, 1,1-dimethylethyl ester
• Synonyms: tert-butyl (3-bromo-2-fluorophenyl) carbamate;N-Boc-3-bromo-2-fluoroaniline
• CAS NO: 848440-23-3
• Molecular Formula: C11H13BrFNO2
• Molecular Weight: 290.132
• Mol File: 848440-23-3.mol

Chemical Properties

• Boiling Point: 271.2±30.0 °C(Predicted)
• Density: 1.459±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Carbamic acid, (3-bromo-2-fluorophenyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (3-bromo-2-fluorophenyl)-, 1,1-dimethylethyl ester(848440-23-3)
• EPA Substance Registry System: Carbamic acid, (3-bromo-2-fluorophenyl)-, 1,1-dimethylethyl ester(848440-23-3)

Safety Data

• Hazardous Substances Data: 848440-23-3(Hazardous Substances Data)

Upstream product

• 161957-56-8 3-bromo-2-fluorobenzoic acid 
• 75-65-0 tert-butyl alcohol 
• 58534-95-5 3-bromo-2-fluorobenzenamine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1188227-29-3 7-bromo-2-chlorobenzothiazole 
• 58534-95-5 3-bromo-2-fluorobenzenamine 
• 1357588-10-3 {2-fluoro-3-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]phenyl}carbamic acid tert-butyl ester 
• 449758-17-2 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole 
• 1357588-15-8 3-(1-ethyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-2-fluorophenylamine 
• 1357588-14-7 [3-(1-ethyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-2-fluorophenyl]carbamic acid tert-butyl ester 
• 1357588-12-5 [3-(4-bromo-2H-pyrazol-3-yl)-2-fluorophenyl]carbamic acid tert-butyl ester 
• 1357588-11-4 [2-fluoro-3-(2H-pyrazol-3-yl)phenyl]carbamic acid tert-butyl ester 
• 1357587-26-8 N-[3-(1-ethyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-2-fluorophenyl]-3-fluorobenzenesulfonamide 
• 1099766-43-4 tert-butyl [3-(4-hydroxybut-1-yn-1-yl)-2-fluorophenyl]carbamate 

Relevant articles and documents

DIACYLGLYCEROL KINASE MODULATING COMPOUNDS

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof

The present invention provides compounds that can enhance functional O-mannosylation of proteins including alpha-dystroglycan. Also provided are methods of preparation of the compounds defined by the formula I. Also provided are the methods of using the compounds or the pharmaceutical acceptable salts or prodrugs thereof in treating and preventing subjects suffering from the diseases including muscular dystrophies and cancers.

N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS

The invention relates to N-(substituted-phenyl)-sulfonamide compounds, which are extremely useful as inhibitors of protein kinases (e.g. PERK kinase) and accordingly can be used for the treatment of cell proliferative disorders, such as cancer, or diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

NOVEL COMPOUND WITH ANTIBACTERIAL ACTIVITY

A compound represented by the general formula (I) or a salt thereof having a potent antibacterial activity against bacteria that have acquired resistance to quinolones, and a medicament for prophylactic and/or therapeutic treatment of an infectious disease containing the compound or a salt thereof as an active ingredient, as well as a medicament for prophylactic and/or therapeutic treatment of an infectious disease containing a combination of the compound or a salt thereof, and a quinolone.

Small molecules enhance functional O-mannosylation of Alpha-dystroglycan

Alpha-dystroglycan (α-DG), a highly glycosylated receptor for extracellular matrix proteins, plays a critical role in many biological processes. Hypoglycosylation of α-DG results in various types of muscular dystrophies and is also highly associated with progression of majority of cancers. Currently, there are no effective treatments for those devastating diseases. Enhancing functional O-mannosyl glycans (FOG) of α-DG on the cell surfaces is a potential approach to address this unmet challenge. Based on the hypothesis that the cells can up-regulate FOG of α-DG in response to certain chemical stimuli, we developed a cell-based high-throughput screening (HTS) platform for searching chemical enhancers of FOG of α-DG from a large chemical library with 364,168 compounds. Sequential validation of the hits from a primary screening campaign and chemical works led to identification of a cluster of compounds that positively modulate FOG of α-DG on various cell surfaces including patient-derived myoblasts. These compounds enhance FOG of α-DG by almost ten folds, which provide us powerful tools for O-mannosylation studies and potential starting points for the development of drug to treat dystroglycanopathy.

Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors

As a result of the various N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives with a hydroxy moiety synthesized in an effort to discover novel glycogen phosphorylase (GP) inhibitors, 5-chloro-N-(5-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-1H-indole-2

QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS

The invention concerns quinazoline derivatives of the Formula (I); wherein each of R1, R2, W, X1, X2, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions co